Therapeutics used in the treatment of gastric ulcer are based mainly on the use of proton pump inhibitors (PPIs) as well as drugs that reduce HCl production by acting on histamine H2-receptors and those that stimulate mucus synthesis or act as gastric dressings [66–68]. This evidence concerns the gene HRH2 and gastric ulcer.